3.60 (-%)
As of Nov 21, 2024
Source:
We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D (or SEMA4D) biology and that we are currently the only company targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders.
Country | United States |
Headquarters | rochester, new york |
Phone Number | 585-271-2700 |
Industry | manufacturing |
CEO | Maurice Zauderer, Ph.D. |
Website | www.clinicaltrials.gov |